ACRV highlights AP3 AI platform for oncology drug development
ACRV says its AP3 platform supports high-resolution, AI-driven drug development, with lead assets in phase II trials and a preclinical CDK11 inhibitor targeting AML.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.